Search
Nuclear receptor subfamily 4 group A member 3
go.drugbank.com/bio_entities/BE0008998TargetHumansTranscriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. … Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity).
Synonyms: Translocated in extraskeletal chondrosarcomaSerine/threonine-protein kinase Nek4
go.drugbank.com/bio_entities/BE0009498TargetHumansRequired for normal cell cycle arrest in response to double-stranded DNA damage
Synonyms: Never in mitosis A-related kinase 4Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology
Categories: Dopamine D2 Receptor AgonistsCiltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … It is a rare malignancy, with an estimated yearly incidence of 6.5 people per 100,000,[L40749] and is variable in its presentation - some patients may remain entirely asymptomatic, while others may experience
Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cellsLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. … [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL).
Lapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalIt was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.
Synonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamineRivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. … However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
Categories: Factor Xa Inhibitors, Direct factor Xa inhibitorsProducts: RIVAROXABAN DR. REDDY'S, Rivaroxaban 1A Pharma 10 mg – FilmtablettenOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalThe angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. … In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function.
Mixtures: OLMEPRESS D, OLMEDIPIN ® D 20/12.5 TABLETA RECUBIERTACategories: Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs), plainNecitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression
Trimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigationalTrimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. … [A7688,L33020] However, evidence for this mechanism is controversial.[A233215] Trimetazidine is not FDA approved. However, it has been approved in France since 1978.[L33020]